Gilgamesh Pharma Raises $60 Million Series A to Advance Post-Acquisition Neuropsychiatric Pipeline

New updates have been reported about Gilgamesh Pharma.

Gilgamesh Pharma, a clinical-stage neuroscience company formed after AbbVie acquired Gilgamesh Pharmaceuticals and bretisilocin in 2025, has closed an oversubscribed $60 million Series A round to fund its next phase of growth. Led by Satori Neuro with participation from Prime Movers Lab and other institutional investors, the financing supplements capital retained from the AbbVie transaction and an earlier neuroplastogen collaboration and option-to-license deal initiated in 2024.

The new capital will be used to advance Gilgamesh Pharma’s portfolio of novel neuropsychiatric drug candidates, all structured as new chemical entities with composition-of-matter protection, and to expand its discovery platform. The company recently reported statistically significant and clinically meaningful Phase 2 results in major depressive disorder for blixeprodil (GM-1020), a non-competitive NMDA receptor antagonist now moving into late-stage development in 2026, while its cardio-safe ibogaine analog GM-3009 is slated to enter Phase 1 later this year.

Additional internal programs are progressing toward IND-enabling work and early clinical trials, reinforcing a multi-asset pipeline strategy centered on durable improvements in psychiatric outcomes rather than symptom control alone. Management, led by founder and CEO Jonathan Sporn, M.D., frames the Series A as critical to advancing multiple assets in parallel and scaling discovery capabilities in neuropsychiatric disease.

The ongoing collaboration with AbbVie on neuroplastogen therapeutics provides both external validation of Gilgamesh Pharma’s platform and a potential future source of non-dilutive value. Satori Neuro’s chief investment officer, Amy Kruse, cited the firm’s view that Gilgamesh’s science, team, and pipeline could materially reshape treatment paradigms for severe mental health conditions, underscoring investor conviction in the company’s strategic direction.

For executives and investors, the deal marks Gilgamesh Pharma’s first formal stand-alone capital raise as a post-spinout entity and positions the company to deliver late-stage data, initiate new clinical programs, and potentially structure future partnering deals from a strengthened balance sheet. The combination of fresh equity, legacy AbbVie-related capital, and an advancing clinical pipeline provides a clearer line of sight to value inflection points over the next 12 to 24 months.